Clinical Data Touts Antidepressant Trial Data

6/2/09

Newton, MA-based Clinical Data (NASDAQ:CLDA), announced positive results from the second Phase III trial of its antidepressant, vilazodone. In a study of 481 patients, the drug reduced depression symptoms, was well tolerated, and did not seem to result in sexual side effects; the results were similar to those from the first Phase III trial, which were announced in March. Clinical Data says it intends to file for FDA approval of vilazodone by the end of 2009. Development of the drug has been supported in part through the $17 million sale of Clinical Data’s genomics division, Cogenics, to Beckman Coulter (NYSE:BEC), an Orange County, CA life sciences company.

Roxanne is an intern in Xconomy's Boston office. You can reach her at rpalmer@xconomy.com. Follow @

By posting a comment, you agree to our terms and conditions.